Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) traded up 4.5% during mid-day trading on Friday . The stock traded as high as $37.15 and last traded at $36.39. 1,535,179 shares traded hands during trading, an increase of 2,964% from the average session volume of 50,104 shares. The stock had previously closed at $34.82.
Neoleukin Therapeutics Trading Up 4.5 %
The company has a market cap of $341.99 million, a P/E ratio of -11.70 and a beta of 1.11. The business’s fifty day moving average is $34.03 and its 200 day moving average is $32.04.
Institutional Investors Weigh In On Neoleukin Therapeutics
A hedge fund recently bought a new stake in Neoleukin Therapeutics stock. Adage Capital Partners GP L.L.C. bought a new stake in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 310,000 shares of the company’s stock, valued at approximately $1,224,000. Adage Capital Partners GP L.L.C. owned about 3.52% of Neoleukin Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 52.37% of the company’s stock.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
See Also
- Five stocks we like better than Neoleukin Therapeutics
- 3 Small Caps With Big Return Potential
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- 3 Monster Growth Stocks to Buy Now
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.